About E3 ubiquitin-protein ligase TRIP12
E3 ubiquitin-protein ligase TRIP12 (TRIP12) is a protein
from Homo sapiens identified by UniProt accession
Q14669, 2067 residues long.
MolForge cross-references it against 0 known binders and
80 disease associations.
Target properties
| Protein name | E3 ubiquitin-protein ligase TRIP12 |
| UniProt accession | Q14669 |
| Gene | TRIP12 |
| Organism | Homo sapiens |
| Length | 2067 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (80)
Diseases linked to this target (Open Targets).
- Clark-Baraitser syndrome · score 0.74
- neurodegenerative disease · score 0.58
- genetic disorder · score 0.52
- Intellectual disability · score 0.47
- complex neurodevelopmental disorder · score 0.46
- Neurodevelopmental disorder · score 0.45
- body mass index · score 0.41
- lysosomal storage disease · score 0.37
- vital capacity · score 0.36
- Neurodevelopmental delay · score 0.34
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q14669-F1 | alphafold | PREDICTED | 66.77 | — |
Amino-acid sequence (2067 residues)
MSNRPNNNPG GSLRRSQRNT AGAQPQDDSI GGRSHLGQAK HKGYSPPESR KSNSKAPKVQ SNTTSELSRG HLSKRSCSSS SAVIVPQPED PDRANTSERQ KTGQVPKKDN SRGVKRSASP DYNRTNSPSS AKKPKALQHT ESPSETNKPH SKSKKRHLDQ EQQLKSAQSP STSKAHTRKS GATGGSRSQK RKRTESSCVK SGSGSESTGA EERSAKPTKL ASKSATSAKA GCSTITDSSS AASTSSSSSA VASASSTVPP GARVKQGKDQ NKARRSRSAS SPSPRRSSRE KEQSKTGGSS KFDWAARFSP KVSLPKTKLS LPGSSKSETS KPGPSGLQAK LASLRKSTKK RSESPPAELP SLRRSTRQKT TGSCASTSRR GSGLGKRGAA EARRQEKMAD PESNQEAVNS SAARTDEAPQ GAAASSSVAG AVGMTTSGES ESDDSEMGRL QALLEARGLP PHLFGPLGPR MSQLFHRTIG SGASSKAQQL LQGLQASDES QQLQAVIEMC QLLVMGNEET LGGFPVKSVV PALITLLQME HNFDIMNHAC RALTYMMEAL PRSSAVVVDA IPVFLEKLQV IQCIDVAEQA LTALEMLSRR HSKAILQAGG LADCLLYLEF FSINAQRNAL AIAANCCQSI TPDEFHFVAD SLPLLTQRLT HQDKKSVEST CLCFARLVDN FQHEENLLQQ VASKDLLTNV QQLLVVTPPI LSSGMFIMVV RMFSLMCSNC PTLAVQLMKQ NIAETLHFLL CGASNGSCQE QIDLVPRSPQ ELYELTSLIC ELMPCLPKEG IFAVDTMLKK GNAQNTDGAI WQWRDDRGLW HPYNRIDSRI IEAAHQVGED EISLSTLGRV YTIDFNSMQQ INEDTGTARA IQRKPNPLAN SNTSGYSESK KDDARAQLMK EDPELAKSFI KTLFGVLYEV YSSSAGPAVR HKCLRAILRI IYFADAELLK DVLKNHAVSS HIASMLSSQD LKIVVGALQM AEILMQKLPD IFSVYFRREG VMHQVKHLAE SESLLTSPPK ACTNGSGSMG STTSVSSGTA TAATHAAADL GSPSLQHSRD DSLDLSPQGR LSDVLKRKRL PKRGPRRPKY SPPRDDDKVD NQAKSPTTTQ SPKSSFLASL NPKTWGRLST QSNSNNIEPA RTAGGSGLAR AASKDTISNN REKIKGWIKE QAHKFVERYF SSENMDGSNP ALNVLQRLCA ATEQLNLQVD GGAECLVEIR SIVSESDVSS FEIQHSGFVK QLLLYLTSKS EKDAVSREIR LKRFLHVFFS SPLPGEEPIG RVEPVGNAPL LALVHKMNNC LSQMEQFPVK VHDFPSGNGT GGSFSLNRGS QALKFFNTHQ LKCQLQRHPD CANVKQWKGG PVKIDPLALV QAIERYLVVR GYGRVREDDE DSDDDGSDEE IDESLAAQFL NSGNVRHRLQ FYIGEHLLPY NMTVYQAVRQ FSIQAEDERE STDDESNPLG RAGIWTKTHT IWYKPVREDE ESNKDCVGGK RGRAQTAPTK TSPRNAKKHD ELWHDGVCPS VSNPLEVYLI PTPPENITFE DPSLDVILLL RVLHAISRYW YYLYDNAMCK EIIPTSEFIN SKLTAKANRQ LQDPLVIMTG NIPTWLTELG KTCPFFFPFD TRQMLFYVTA FDRDRAMQRL LDTNPEINQS DSQDSRVAPR LDRKKRTVNR EELLKQAESV MQDLGSSRAM LEIQYENEVG TGLGPTLEFY ALVSQELQRA DLGLWRGEEV TLSNPKGSQE GTKYIQNLQG LFALPFGRTA KPAHIAKVKM KFRFLGKLMA KAIMDFRLVD LPLGLPFYKW MLRQETSLTS HDLFDIDPVV ARSVYHLEDI VRQKKRLEQD KSQTKESLQY ALETLTMNGC SVEDLGLDFT LPGFPNIELK KGGKDIPVTI HNLEEYLRLV IFWALNEGVS RQFDSFRDGF ESVFPLSHLQ YFYPEELDQL LCGSKADTWD AKTLMECCRP DHGYTHDSRA VKFLFEILSS FDNEQQRLFL QFVTGSPRLP VGGFRSLNPP LTIVRKTFES TENPDDFLPS VMTCVNYLKL PDYSSIEIMR EKLLIAAREG QQSFHLS
Explore E3 ubiquitin-protein ligase TRIP12 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets